BTC
CARM

Bank & Trust Company’s Carisma Therapeutics CARM Stock Holding History

Bank & Trust Company’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-525
Closed -$206 – 289
2025
Q2 		$206 Hold
525
– – ﹤0.01% 286
2025
Q1 		$163 Hold
525
– – ﹤0.01% 289
2024
Q4 		$220 Hold
525
– – ﹤0.01% 285
2024
Q3 		$515 Hold
525
– – ﹤0.01% 285
2024
Q2 		$798 Buy
+525
New +$783 ﹤0.01% 285

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return

Bank & Trust Company's CARM Position: Q3 2025 in Review

Bank & Trust Company sold out of Carisma Therapeutics (CARM) in Q3 2025, closing a stake of 525 shares — an estimated $206 sold.

Bank & Trust Company first reported a position in CARM in Q2 2024 and held it in 5 quarters. The position peaked at $798 in Q2 2024. 33 funds tracked by Wall St. Rank hold CARM as of Q3 2025.

  • Bank & Trust Company reported no remaining Carisma Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank & Trust Company sold 525 Carisma Therapeutics shares in Q3 2025, an estimated $206.
  • Bank & Trust Company first reported a position in Carisma Therapeutics in Q2 2024 and held it in 5 quarters.
  • Bank & Trust Company's Carisma Therapeutics position peaked at $798 in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2025.

Based on Bank & Trust Company's 13F filing for Q3 2025, filed 6 Oct 2025.